search
Back to results

United Kingdom User Evaluation, MiniMed Paradigm® X54 System (X54User)

Primary Purpose

Diabetes Mellitus, Type 1

Status
Completed
Phase
Phase 4
Locations
United Kingdom
Study Type
Interventional
Intervention
X54 insulin pump with low suspend feature
Sponsored by
Medtronic Diabetes
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional other trial for Diabetes Mellitus, Type 1

Eligibility Criteria

18 Years - 65 Years (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • Are current 512/712, 515/715 or 522/722 MiniMed Paradigm Insulin Pump users, with or without CGM experience, and have at least three months experience with any one of these devices;
  • Have signed an Informed Consent and are willing to comply with the user evaluation procedures;
  • Have an HbA1c value less than 9.0% recorded at the time of their last test (if no HbA1c value is available within three months of enrollment, an HbA1c should be performed prior to entry to verify inclusion criteria);
  • Are willing to use the Bolus Wizard feature;
  • Agree to complete a diary for the duration of the study;
  • Agree to complete a questionnaire at the conclusion of the study;
  • Have been diagnosed with Type 1 Diabetes Mellitus by appropriate fasting or non fasting lab blood glucose values, c-peptide, insulin antibodies, prior documented DKA or good clinical picture at least six months prior to study start;
  • Are 18 - 65 years of age;
  • Have access to the internet and agree to upload the device per protocol

Exclusion Criteria:

  • Is pregnant or planning to become pregnant during the course of the user evaluation. Pregnancy screening will be completed during the routine office visit prior to evaluation for the study. If a woman becomes pregnant during participation, she will be withdrawn;
  • Suffers from a chronic debilitating condition;
  • Has serious or unstable medical or psychological conditions (e.g., eating disorders, clinical depression, anxiety disorder) which, in the opinion of the Investigator, would compromise the subject's safety or successful participation in the study;
  • Has impaired vision or hearing problems that could compromise the handling of the device;
  • Has a history of tape allergies or skin conditions that could interfere with continued use of the system;
  • Has the potential for lack of compliance or any other issue, in the opinion of the Investigator, that may preclude the subject from satisfactory participation in the study;
  • Has travel plans which would make it difficult for the subject to attend on-site study visits as scheduled;
  • Is currently participating in an investigational study (drug or device).

Sites / Locations

  • Addenbrookes Hospital
  • Royal Bournemouth Hospital
  • Kings College Hospital
  • Harrogate District Hospital
  • Newcastle General Hospital
  • Guy's Hospital

Arms of the Study

Arm 1

Arm Type

Experimental

Arm Label

X54 pump

Arm Description

All subjects transferred from current pump to X54

Outcomes

Primary Outcome Measures

Usability of the X54 Insulin Pump Meets Expectations
Questionnaire completed at the end of the study measuring usability of the X54 insulin pump. Results scored on a Likert scale of 1 - 7, 1 being the least likely to use and 7 being the most likely to use.

Secondary Outcome Measures

Usability of the Training Material Meets Expectations
Questionnaire completed at the end of the study, measuring usability of the device training manual. Results scored on a Likert scale of 1 - 7, 1 being the least user friendly and 7 being the most user friendly.

Full Information

First Posted
December 23, 2010
Last Updated
June 21, 2023
Sponsor
Medtronic Diabetes
search

1. Study Identification

Unique Protocol Identification Number
NCT01267175
Brief Title
United Kingdom User Evaluation, MiniMed Paradigm® X54 System
Acronym
X54User
Official Title
United Kingdom User Evaluation, MiniMed Paradigm® X54 System
Study Type
Interventional

2. Study Status

Record Verification Date
June 2023
Overall Recruitment Status
Completed
Study Start Date
January 2009 (undefined)
Primary Completion Date
February 2009 (Actual)
Study Completion Date
February 2009 (Actual)

3. Sponsor/Collaborators

Name of the Sponsor
Medtronic Diabetes

4. Oversight

Data Monitoring Committee
No

5. Study Description

Brief Summary
The user evaluation is to assess user acceptance and the quality of training materials for the MiniMed Paradigm® X54 System (X54 System) in preparation for commercial distribution of the new system.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Diabetes Mellitus, Type 1

7. Study Design

Primary Purpose
Other
Study Phase
Phase 4
Interventional Study Model
Single Group Assignment
Masking
None (Open Label)
Allocation
Non-Randomized
Enrollment
31 (Actual)

8. Arms, Groups, and Interventions

Arm Title
X54 pump
Arm Type
Experimental
Arm Description
All subjects transferred from current pump to X54
Intervention Type
Device
Intervention Name(s)
X54 insulin pump with low suspend feature
Other Intervention Name(s)
Veo
Intervention Description
Change from current insulin pump to new X54 pump
Primary Outcome Measure Information:
Title
Usability of the X54 Insulin Pump Meets Expectations
Description
Questionnaire completed at the end of the study measuring usability of the X54 insulin pump. Results scored on a Likert scale of 1 - 7, 1 being the least likely to use and 7 being the most likely to use.
Time Frame
5 weeks
Secondary Outcome Measure Information:
Title
Usability of the Training Material Meets Expectations
Description
Questionnaire completed at the end of the study, measuring usability of the device training manual. Results scored on a Likert scale of 1 - 7, 1 being the least user friendly and 7 being the most user friendly.
Time Frame
5 weeks

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
65 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Are current 512/712, 515/715 or 522/722 MiniMed Paradigm Insulin Pump users, with or without CGM experience, and have at least three months experience with any one of these devices; Have signed an Informed Consent and are willing to comply with the user evaluation procedures; Have an HbA1c value less than 9.0% recorded at the time of their last test (if no HbA1c value is available within three months of enrollment, an HbA1c should be performed prior to entry to verify inclusion criteria); Are willing to use the Bolus Wizard feature; Agree to complete a diary for the duration of the study; Agree to complete a questionnaire at the conclusion of the study; Have been diagnosed with Type 1 Diabetes Mellitus by appropriate fasting or non fasting lab blood glucose values, c-peptide, insulin antibodies, prior documented DKA or good clinical picture at least six months prior to study start; Are 18 - 65 years of age; Have access to the internet and agree to upload the device per protocol Exclusion Criteria: Is pregnant or planning to become pregnant during the course of the user evaluation. Pregnancy screening will be completed during the routine office visit prior to evaluation for the study. If a woman becomes pregnant during participation, she will be withdrawn; Suffers from a chronic debilitating condition; Has serious or unstable medical or psychological conditions (e.g., eating disorders, clinical depression, anxiety disorder) which, in the opinion of the Investigator, would compromise the subject's safety or successful participation in the study; Has impaired vision or hearing problems that could compromise the handling of the device; Has a history of tape allergies or skin conditions that could interfere with continued use of the system; Has the potential for lack of compliance or any other issue, in the opinion of the Investigator, that may preclude the subject from satisfactory participation in the study; Has travel plans which would make it difficult for the subject to attend on-site study visits as scheduled; Is currently participating in an investigational study (drug or device).
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Scott W Lee, MD
Organizational Affiliation
Medtronic
Official's Role
Study Director
Facility Information:
Facility Name
Addenbrookes Hospital
City
Cambridge
State/Province
Cambridgeshire
ZIP/Postal Code
CB2 0QQ
Country
United Kingdom
Facility Name
Royal Bournemouth Hospital
City
Bournemouth
State/Province
Dorset
ZIP/Postal Code
BH7 7DW
Country
United Kingdom
Facility Name
Kings College Hospital
City
Denmark Hill
State/Province
London
ZIP/Postal Code
SE5 9RS
Country
United Kingdom
Facility Name
Harrogate District Hospital
City
Harrogate
State/Province
N. Yorkshire
ZIP/Postal Code
HG2 7SX
Country
United Kingdom
Facility Name
Newcastle General Hospital
City
Newcastle Upon Tyne
State/Province
Tyne And Wear
ZIP/Postal Code
NE4 6BE
Country
United Kingdom
Facility Name
Guy's Hospital
City
London
ZIP/Postal Code
SE1 9RT
Country
United Kingdom

12. IPD Sharing Statement

Citations:
PubMed Identifier
21868778
Citation
Choudhary P, Shin J, Wang Y, Evans ML, Hammond PJ, Kerr D, Shaw JA, Pickup JC, Amiel SA. Insulin pump therapy with automated insulin suspension in response to hypoglycemia: reduction in nocturnal hypoglycemia in those at greatest risk. Diabetes Care. 2011 Sep;34(9):2023-5. doi: 10.2337/dc10-2411.
Results Reference
derived

Learn more about this trial

United Kingdom User Evaluation, MiniMed Paradigm® X54 System

We'll reach out to this number within 24 hrs